Compare EBS & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EBS | DSU |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.3M | 548.1M |
| IPO Year | 2006 | N/A |
| Metric | EBS | DSU |
|---|---|---|
| Price | $13.20 | $10.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 788.6K | 148.2K |
| Earning Date | 10-29-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $788,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.21 | N/A |
| P/E Ratio | $9.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.02 | $9.22 |
| 52 Week High | $13.41 | $11.40 |
| Indicator | EBS | DSU |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 46.47 |
| Support Level | $12.02 | $10.20 |
| Resistance Level | $12.90 | $10.28 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 75.00 | 28.57 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.